Market revenue in 2023 | USD 280.2 million |
Market revenue in 2030 | USD 463.3 million |
Growth rate | 7.4% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Manufacturing, Contract Development |
Key market players worldwide | Eurofins Scientific SE, WuXi Biologics (Cayman) Inc, Catalent Inc, AGC Inc, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Holdings Corp, Samsung BioLogics, Rentschler Biopharma SE, Recipharm |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule drug substance cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 67.02% in 2023. Horizon Databook has segmented the Canada large molecule drug substance cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2018 to 2030.
Key factor driving the large molecule drug substance development market in Canada is the presence of regulatory bodies like Biologics and Genetic Therapies Directorate (BGTD) of the Health Products and Food Branch (HPFB) of Health Canada in the country.
BGTD is engaged in the regulation of biological products, including hemostatic agents, blood & blood products, hormones, bacterial & viral vaccines, gene & cell therapies cytokines, enzymes, allergenic extracts, monoclonal antibodies, developed in the country.
Increase in R&D being conducted externally and through partnerships by receive funding and investment from small- & medium-sized enterprises and other venture funds is expected to drive demand for biopharmaceutical manufacturing in the country in the near future.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada large molecule drug substance cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Canada large molecule drug substance cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account